TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01439815
Drug: Fluticasone Propionate Nasal Spray
Normalized name: fluticasone propionate Metered Dose Nasal Spray
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: two sprays in each nostril once daily
Study: NCT00003673
Drug: gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01581073
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa is used for targeting Hb level of 11-13g/dL in high Hb group, and 9-11g/dL in low Hb group.
Study: NCT01274273
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 MIU/m2 s.c. two times daily, 5 days per week, weeks 1 and 2, every 28-day-cycle, for a maximum of 9 cycles (i.e.for a maximum of 9 months).
Study: NCT01274273
Drug: Interferon Alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IFN-alfa given as one priming-week of daily IFN 3.0 MIU, followed by up to 9 treatment cycles (i.e. for a maximum of 9 months) with IFN-alfa 3.0 MIU as a fixed dose s.c. once daily - 5 days per week.
Study: NCT01274273
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab doses of 10 mg per kilogram of body weight, given every two weeks i.v. until disease progression, unacceptable toxicity, withdrawal of consent or a maximum of 1 year following obtaining no evidence of disease (NED).
Study: NCT01204073
Drug: TAK-441
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-441 will be administered as an oral tablet as follows:~Patients enrolled in the dose escalation cohorts will receive:~* A single-dose administration on Day 1, followed by a 1-week washout period during which pharmacokinetics is assessed~* Continuous daily dosing on Days 8 through 28 in Cycle 1~* In subsequent cycles, continuous daily dosing over 21 days, repeated continuously~Patients enrolled in the expansion cohorts will receive continuous daily dosing on Days 1 through 21 of each 21-day cycle
Study: NCT04315831
Drug: Transdermal Buprenorphine
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intervention will be applied for patients with moderate to severe cancer pain
Study: NCT02996448
Drug: NDV-3A
Normalized name: GD-HP-DO 3A
DrugBank: Gadoteridol (DB00597)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A vaccine containing recombinant Candida albicans agglutinin-like sequence 3 (rAls3) protein as the antigen, formulated with AlOH adjuvant in phosphate buffered saline. Participants will receive a single 0.5 mL dose containing 300 micrograms of rAls3 and 0.5 mg of aluminum as AlOH, delivered via intramuscular injection.
Study: NCT01093040
Drug: CAT-354
Normalized name: Spotted cat
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg CAT-354 or placebo given SC on Day 1
Study: NCT01093040
Drug: CAT-354
Normalized name: Spotted cat
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg CAT-354 or placebo given SC on Day 1
Study: NCT01093040
Drug: CAT 354
Normalized name: Spotted cat
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg CAT-354 or placebo given SC on Day 1
Study: NCT00368914
Drug: sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00732784
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dosage form: tablets Dosage: 400 mg Frequency \& duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
Study: NCT01018342
Drug: Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg
DrugBank: Nitrofurantoin (DB00698)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01035593
Drug: recombinant C1 inhibitor
Normalized name: C1 Inhibitor (Recombinant)
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100units/kg IV for seven consecutive days (once daily on PP/IVIG days, twice daily on non-PP/IVIG days).
Study: NCT00315328
Drug: Atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine 1% each weekend day in the sound eye
Study: NCT00984828
Drug: velcade
Normalized name: Velcade
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: velcade 1.3mg/m2 D1, 4, 8 and 11
Study: NCT00753909
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin (IV) 3 AUC on day 1 and day 15 every 4 weeks for 6 cycles
Study: NCT00753909
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (IV) 10 mg/kg on day 1 and day 15 every 4 weeks for 6 cycles Followed by Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression
Study: NCT00753909
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (IV) 140 mg/m2,on day 1 and day 15 every 4 weeks for 6 cycles
Study: NCT01447212
Drug: Hydromorphone, Injectable
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase I: 3x daily, up to 500mg per day, for 6 months. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable hydromorphone; 2) switch to oral hydromorphone, for another 6 months.
Study: NCT01447212
Drug: Diacetylmorphine, injectable
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase I: 3x daily, up to 1,000mg per day, for 6 months. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable diacetylmorphine; 2) switch to oral diacetylmorphine, for another 6 months.
Study: NCT01447212
Drug: Hydromorphone, liquid oral
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study Phase II: After 6 months of receiving Hydromorphone injectable , participants will be randomized to stay on injectable hydromorphone or switch to oral hydromorphone, for another six months. Oral = experimental; injectable = active comparator
Study: NCT01019278
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00791154
Drug: AMG 479
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 479 is administered to subjects
Study: NCT01447212
Drug: Diacetylmorphine, liquid oral
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study Phase II: After 6 months of receiving Diacetylmorphine injectable, participants will be randomized to stay on injectable Diacetylmorphine or switch to oral Diacetylmorphine, for another six months. Oral = experimental; injectable = active comparator
Study: NCT01086527
Drug: 10 mg tablet of montelukast (Singulair)
Normalized name: montelukast 10 MG
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fasting patients will take a single 10 mg tablet of montelukast with 240 ml of Gatorade. Eight blood samples will be drawn to assess the plasma concentration of montelukast over the subsequent 12 hours.
Study: NCT00791154
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide is administered to subjects
Study: NCT02232880
Drug: Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day \[Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day\], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase.
Study: NCT01585584
Drug: Boceprevir
Normalized name: Boceprevir
DrugBank: Boceprevir (DB08873)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will receive a 4-week lead-in with Peginterferon and Ribavirin therapy, followed by 24 weeks of Pegetron 1.5microg/kg + weight-based ribavirin + boceprevir 800mg tid. HCV RNA (Cobas TaqMan) will be measured at baseline and at treatment weeks 4, 6,8,12,16,20,24 and 28, and post-treatment weeks 12 and 24 (to obtain SVR-12 and SVR-24 results).
Study: NCT00527488
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two doses of 16 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
Study: NCT00527488
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of 32 mg administered as a single administration will be evaluated for 42 days.
Study: NCT00791154
Drug: AMG 102
Normalized name: AMG 102
DrugBank: Rilotumumab (DB11972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 102 is administered to subjects
Study: NCT00791154
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin is administered to some subjects in combination
Study: NCT00791154
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin is administered to some subjects in combination
Study: NCT00527488
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two doses of 32 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
Study: NCT00527488
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of 64 mg administered as a single administration will be evaluated for 42 days.
Study: NCT02848443
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Concentrate for solution for infusion containing 5mg/ml of oxaliplatin, administered intravenously at the dose of 65 to 85 mg/m2, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
Study: NCT02848443
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Concentrate for solution for infusion containing 25mg/ml of bevacizumab, administered intravenously at the dose of 5 mg/kg, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
Study: NCT02848443
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Concentrate for solution for infusion containing 10mg/ml of nivolumab, administered intravenously at the dose of 3 mg/kg, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
Study: NCT00997672
Drug: Lithium Carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day.
Study: NCT03874260
Drug: Fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate vs statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate placebo / once a day, P.O
Study: NCT01728363
Drug: Antibiotic
Normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticarcillin-clavulanate/Timentin is an antibiotic used to treat a wide variety of bacterial infections. Rifampin/Rifadin/Rimatane is an antibiotic and first line antituberculotic. Clindamycin/Cleocin is an antibiotic used to treat a wide variety of bacterial infections and serious bacterial infections.
Study: NCT00004393
Drug: risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03739996
Drug: Long-Acting Injectable Cabotegravir (CAB LA)
DrugBank: Cabotegravir (DB11751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mg loading dose followed by 400 mg maintenance doses administered by intramuscular (IM) injection
Study: NCT00534261
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IM injection
Study: NCT01967381
Drug: Methamphetamine (Desoxyn®)
Normalized name: methamphetamine Oral Tablet [Desoxyn]
DrugBank: Metamfetamine (DB01577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The pharmacodynamic effects of methamphetamine (Desoxyn®) will be determined during placebo, oxazepam (Serax®), naltrexone (Revia®) and combined oxazepam and naltrexone maintenance.
Study: NCT03716804
Drug: Tablet Nitrofurantoin
Normalized name: nitrofurantoin Oral Tablet
DrugBank: Nitrofurantoin (DB00698)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet Nitrofurantoin (100 mg), two times daily in 12 hours interval for 7 days
Study: NCT03460015
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During the first 30 minutes after randomization, patients will be treated with propofol (same dosage as the propofol group).~Once the AnaConDa® system is installed, sevoflurane administration will begin (propofol is stopped).
Study: NCT03460015
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the control group, sedation will be maintained with the above objective (RASS between -4 and -5, BIS between 40 and 60) until the patient is extubated.~In the sevoflurane group, propofol is administrated during the first 30 minutes after the randomization and when the AnaConDa® system is installed propofol is stopped.
Study: NCT03757013
Drug: Apremilast
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apremilast
Study: NCT00139867
Drug: PARCOPA
Normalized name: Parcopa
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02955251
Drug: ABBV-428
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBV-428 will be administered by intravenous infusion in 28-day dosing cycles on Day 1 and Day 15.
Study: NCT02955251
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab will be administered by intravenous infusion according to approved dose and dosing schedules.
Study: NCT00729222
Drug: rolofylline
Normalized name: Rolofylline
DrugBank: Rolofylline (DB12670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rolofylline 30 mg IV infusion over 4 hours.
Study: NCT02850081
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A lipid-lowering agent and for prevention of events associated with cardiovascular disease.~10 mg or 80 mg capsules
Study: NCT00627146
Drug: ChAgly CD3
Normalized name: Muromonab-Cd3
DrugBank: Muromonab (DB00075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 days treatment 8mg/d intravenous
Study: NCT01145638
Drug: iron isomaltoside 1000
Normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenously as bolus or infusion, 500 mg or 1000mg up to full replacement dose
Study: NCT00789074
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Varenicline 1mg twice daily
Study: NCT01974765
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All enrolled patients will be treated with enzalutamide 160mg by mouth QD. Study drugs will be self-administered by patients. A cycle is 28 days.
Study: NCT01528865
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Creatinine Clearance (mL/min): ≥50, Recommended Dosage of Epivir: 150 mg twice daily or 300 mg once daily.~Creatinine Clearance (mL/min): 30-49, Recommended Dosage of Epivir: 150 mg once daily.~Subjects will be taking drug for 16 weeks.
Study: NCT01528865
Drug: Tenofovir disoproxil fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg once a day p.o. for 16 weeks.
Study: NCT04531462
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin
Study: NCT00002920
Drug: medroxyprogesterone
Normalized name: Medroxyprogesterone
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002920
Drug: tamoxifen citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02307864
Drug: Tramadol HCl
Normalized name: tramadol HCl
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol HCl 50 mg immediate release (IR) tablet administered orally.
Study: NCT02307864
Drug: Moxifloxacin 400 mg
Normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg tablet administered orally.
Study: NCT02307864
Drug: Tramadol HCl Placebo
Normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Placebo matched to tramadol HCl IR tablet administered orally.
Study: NCT04437160
Drug: Epirubicin or Pirarubicin
Normalized name: pirarubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin 80-90mg/m2 IV or Pirarubicin 50mg/m2 IV, q21d\*4cycls
Study: NCT03702803
Drug: alprazolam 1mg
Normalized name: ALPRAZOLAM 1MG TAB
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each patient will be administered once a day (in the morning) for 10 weeks. A capsule contains 1 mg Alprazolam
Study: NCT00148551
Drug: Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00886873
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02629627
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin in a dosis of 500mg per day (with the first bite of the second meal) during 12 weeks
Study: NCT02292784
Drug: Retosiban
Normalized name: Retosiban
DrugBank: Retosiban (DB11818)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a safety follow-up study of infants and children exposed to retosiban during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product.
Study: NCT02292784
Drug: Atosiban
Normalized name: atosiban
DrugBank: Atosiban (DB09059)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: This is a safety follow-up study of infants and children exposed to atosiban comparator during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product.
Study: NCT00844168
Drug: sorafenib tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT03033498
Drug: ABBV-951
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBV-951 administered by subcutaneous infusion.
Study: NCT03134573
Drug: Interferon beta-1b (Betaferon, BAY86-5046)
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution for injection
Study: NCT03747939
Drug: Apremilast (CC-10004)
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects randomized to apremilast will receive dose-titration for the initial 5 days. Apremilast subjects will receive dummy titration at wk. 16 (for early escape subjects) and again at week 24 to maintain the blinding of the original treatment assignments. Investigational product (IP) will be dispensed in blinded dose cards until Week 28. Thereafter, IP will be dispensed in open-label bottles.
Study: NCT02365766
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In this dose-finding cohort, pembrolizumab (MK-3475) will be administered (cisplatin-eligible patients only) at starting dose 200mg IV every 21 days for 4 cycles to determine RP2D. Once MTD is established in phase Ib, pembrolizumab will be administered on phase II cohorts I and II at RP2D every 21 days for 5 cycles.
Study: NCT02365766
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For cisplatin-eligible patients on phase Ib and phase II cohort 1, gemcitabine 1000mg/m2 IV, D1 and D8 every 21 days for 4 cycles. For cisplatin-ineligible patients on phase II cohort II, gemcitabine 1000mg/m2 will be administered D1, D8 and D15 every 28 days for 3 cycles.
Study: NCT02365766
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For cisplatin-eligible patients, cisplatin 70mg/m2 IV will be administered D1 every 21 days for 4 cycles.
Study: NCT03856658
Drug: Floxuridine (FUDR)
Normalized name: Floxuridine
DrugBank: Floxuridine (DB00322)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Together the FUDR and the HAI pump are experimental because they are being used to treat hepatic liver metastases of Pancreatic adenocarcinoma. They have not yet been FDA approved for this indication, although they are both approved for other indications. The intervention is surgical placement of an HAI pump with subsequent delivery of FUDR via the pump in 28-day cycles. FUDR will be delivered via the HAI pump for 6 months, in 28 day cycles: 2 weeks of therapy, followed by 2 weeks of heparinized saline.
Study: NCT00852332
Drug: Taxotere
Normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04179409
Drug: Amondys 45
Normalized name: Amondys 45
DrugBank: Casimersen (DB14984)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This drug is used to target skipping of exon 45 of the dystrophin gene.
Study: NCT04179409
Drug: Exondys 51
Normalized name: Exondys 51
DrugBank: Eteplirsen (DB06014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This drug is used to target skipping of exon 51 of the dystrophin gene.